20 Acorn Park Drive
Tel: (617) 949-4359
About Omega Therapeutics
About Omega Epigenomic Controllers™ and Omega Epigenomic Programming™
Omega Therapeutics is developing a new class of engineered and modular therapeutics, called Omega Epigenomic Controllers™, that can be programmed to precisely downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease. Omega Epigenomic Programming™ represents an entirely new and 3 breakthrough approach, allowing the Company’s product candidates to drug previously undruggable targets across a broad range of diseases. The foundation of Omega’s platform lies within the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and conserved structures called Insulated Genomic Domains (IGDs). Omega’s technology exploits the topology and functionality of these IGDs as druggable targets to activate the genome’s innate ability to treat and cure disease. Omega’s medicines are being developed to be dosed only as frequently as therapeutically necessary by intervening at the pre-transcriptional level and function without altering the native human genetic code or nucleic acid sequences.
About Omega Therapeutics
Omega Therapeutics is a privately held, development-stage biotechnology company pioneering the field of epigenomic programming to precisely regulate and control the human genome to treat and cure disease. Omega’s breakthrough science has enabled it to tap into nature’s universal operating system, that epigenetically controls the human genome, to target the most fundamental genomic processes which fuel cellular growth, differentiation, and gene expression. Omega Therapeutics was founded by Flagship Pioneering in 2017 and currently has eight programs in various stages of preclinical development. The Company is strategically pursuing specific disease targets that have not been successfully addressed through conventional modalities, including certain oncology indications, liver disease, serious inflammatory conditions, and acute respiratory distress syndrome (ARDS) among others. Omega’s mission is to transform medicine and deliver the therapies of tomorrow.
9 articles with Omega Therapeutics
5/21/2021Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Omega Therapeutics Strengthens Board of Directors with Appointment of R&D Veteran Elliott M. Levy, M.D.
Industry R&D Leader Brings Over Two Decades of Senior Leadership Experience at Amgen and Bristol-Myers Squibb joins Omega Therapeutics
3/31/2021Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing
Additional Capital from Flagship Pioneering, Joined by Invus, Fidelity Management & Research Company, Funds and Accounts Managed by BlackRock, Cowen, and Others
Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.
Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.
Omega Therapeutics Announces the Industry's First Programmable Epigenetic Medicine in Development and 2021 Priorities
OTX-2002 To Be Developed for the Treatment of MYC-Driven Hepatocellular Carcinoma Company is Advancing Candidate Into IND-Enabling Studies, with the Goal of Commencing a Phase 1/2 Clinical Trial Thereafter
Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the field of Epigenomic Programming™ to precisely regulate and control the human genome to treat and cure disease, today announced that Mahesh Karande , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Heal
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.